These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 29277785)

  • 1. Establishment of a Patient-derived Xenograft for Development of Personalized HER2-targeting Therapy in Gastric Cancer.
    Shin SH; Park SS; Ju EJ; Park J; Ko EJ; Hwang JJ; Suh YA; Jang SJ; Lee JS; Ko BK; Kim KT; Lee JS; Song SY; Jeong SY; Choi EK
    Anticancer Res; 2018 Jan; 38(1):287-293. PubMed ID: 29277785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
    BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized therapeutic strategies in HER2-driven gastric cancer.
    Ughetto S; Migliore C; Pietrantonio F; Apicella M; Petrelli A; D'Errico L; Durando S; Moya-Rull D; Bellomo SE; Rizzolio S; Capelôa T; Ribisi S; Degiuli M; Reddavid R; Rapa I; Fumagalli U; De Pascale S; Ribero D; Baronchelli C; Sgroi G; Rausa E; Baiocchi GL; Molfino S; Manenti S; Bencivenga M; Sacco M; Castelli C; Siena S; Sartore-Bianchi A; Tosi F; Morano F; Raimondi A; Prisciandaro M; Gloghini A; Marsoni S; Sottile A; Sarotto I; Sapino A; Marchiò C; Cassoni P; Guarrera S; Corso S; Giordano S
    Gastric Cancer; 2021 Jul; 24(4):897-912. PubMed ID: 33755862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination photoimmunotherapy with monoclonal antibodies recognizing different epitopes of human epidermal growth factor receptor 2: an assessment of phototherapeutic effect based on fluorescence molecular imaging.
    Ito K; Mitsunaga M; Nishimura T; Kobayashi H; Tajiri H
    Oncotarget; 2016 Mar; 7(12):14143-52. PubMed ID: 26909859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-nanoparticle conjugate constructed with trastuzumab and nanoparticle albumin-bound paclitaxel for targeted therapy of human epidermal growth factor receptor 2-positive gastric cancer.
    Xiong J; Han S; Ding S; He J; Zhang H
    Oncol Rep; 2018 Mar; 39(3):1396-1404. PubMed ID: 29328489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
    Saeki H; Oki E; Kashiwada T; Arigami T; Makiyama A; Iwatsuki M; Narita Y; Satake H; Matsuda Y; Sonoda H; Shimokawa M; Maehara Y;
    Eur J Cancer; 2018 Dec; 105():41-49. PubMed ID: 30391779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-301a-3p induced by endoplasmic reticulum stress mediates the occurrence and transmission of trastuzumab resistance in HER2-positive gastric cancer.
    Guo J; Zhong X; Tan Q; Yang S; Liao J; Zhuge J; Hong Z; Deng Q; Zuo Q
    Cell Death Dis; 2021 Jul; 12(7):696. PubMed ID: 34257270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models.
    Chen H; Ye Q; Lv J; Ye P; Sun Y; Fan S; Su X; Gavine P; Yin X
    Pathol Oncol Res; 2015 Sep; 21(4):947-55. PubMed ID: 25749810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 2.
    Wu J; Zhao Q; Zhao Y; Zhang X; Tian Y; Guo Z
    Sci Rep; 2021 Mar; 11(1):6993. PubMed ID: 33772068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer.
    Wang Q; Zhang X; Shen E; Gao J; Cao F; Wang X; Li Y; Tian T; Wang J; Chen Z; Wang J; Shen L
    Cancer Lett; 2016 Sep; 380(1):20-30. PubMed ID: 27317872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YAP inhibition overcomes adaptive resistance in HER2-positive gastric cancer treated with trastuzumab via the AKT/mTOR and ERK/mTOR axis.
    Qiao J; Feng M; Zhou W; Tan Y; Yang S; Liu Q; Wang Q; Feng W; Pan Y; Cui L
    Gastric Cancer; 2024 Jul; 27(4):785-801. PubMed ID: 38782859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of
    Guo X; Zhou N; Chen Z; Liu T; Xu X; Lei X; Shen L; Gao J; Yang Z; Zhu H
    Gastric Cancer; 2020 Jul; 23(4):614-626. PubMed ID: 31919745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab Inhibits Growth of HER2-Negative Gastric Cancer Cells Through Gastrin-Initialized CCKBR Signaling.
    Cui Y; Li SB; Peng XC; Wu J; Fu GH
    Dig Dis Sci; 2015 Dec; 60(12):3631-41. PubMed ID: 26173505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Porphyrin modified trastuzumab improves efficacy of HER2 targeted photodynamic therapy of gastric cancer.
    Korsak B; Almeida GM; Rocha S; Pereira C; Mendes N; Osório H; Pereira PMR; Rodrigues JMM; Schneider RJ; Sarmento B; Tomé JPC; Oliveira C
    Int J Cancer; 2017 Oct; 141(7):1478-1489. PubMed ID: 28639285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.
    Pietrantonio F; Fucà G; Morano F; Gloghini A; Corso S; Aprile G; Perrone F; De Vita F; Tamborini E; Tomasello G; Gualeni AV; Ongaro E; Busico A; Giommoni E; Volpi CC; Laterza MM; Corallo S; Prisciandaro M; Antista M; Pellegrinelli A; Castagnoli L; Pupa SM; Pruneri G; de Braud F; Giordano S; Cremolini C; Di Bartolomeo M
    Clin Cancer Res; 2018 Mar; 24(5):1082-1089. PubMed ID: 29208673
    [No Abstract]   [Full Text] [Related]  

  • 16. Noninvasive Detection of HER2 Expression in Gastric Cancer by
    Guo X; Zhu H; Zhou N; Chen Z; Liu T; Liu F; Xu X; Jin H; Shen L; Gao J; Yang Z
    Mol Pharm; 2018 Nov; 15(11):5174-5182. PubMed ID: 30251865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2-Antibody-Drug Conjugate against Refractory HER2-Positive Cancers.
    Shin SH; Park YH; Park SS; Ju EJ; Park J; Ko EJ; Bae DJ; Kim SY; Chung CW; Song HY; Jang SJ; Jeong SY; Song SY; Choi EK
    Adv Sci (Weinh); 2021 Dec; 8(23):e2102414. PubMed ID: 34664433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type.
    Xu C; Liu Y; Jiang D; Li Q; Ge X; Zhang Y; Huang J; Su J; Ji Y; Hou J; Lu S; Hou Y; Liu T
    Oncotarget; 2017 May; 8(20):33185-33196. PubMed ID: 28388541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients.
    Mishima Y; Matsusaka S; Chin K; Mikuniya M; Minowa S; Takayama T; Shibata H; Kuniyoshi R; Ogura M; Terui Y; Mizunuma N; Hatake K
    Target Oncol; 2017 Jun; 12(3):341-351. PubMed ID: 28508152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer.
    Bloom MJ; Jarrett AM; Triplett TA; Syed AK; Davis T; Yankeelov TE; Sorace AG
    BMC Cancer; 2020 Apr; 20(1):359. PubMed ID: 32345237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.